BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 31535081)

  • 1. Critical role of ASCT2-mediated amino acid metabolism in promoting leukaemia development and progression.
    Ni F; Yu WM; Li Z; Graham DK; Jin L; Kang S; Rossi MR; Li S; Broxmeyer HE; Qu CK
    Nat Metab; 2019 Mar; 1(3):390-403. PubMed ID: 31535081
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The glutamine transporter ASCT2 (SLC1A5) promotes tumor growth independently of the amino acid transporter LAT1 (SLC7A5).
    Cormerais Y; Massard PA; Vucetic M; Giuliano S; Tambutté E; Durivault J; Vial V; Endou H; Wempe MF; Parks SK; Pouyssegur J
    J Biol Chem; 2018 Feb; 293(8):2877-2887. PubMed ID: 29326164
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of ASCT2 in cancer: A review.
    Liu Y; Zhao T; Li Z; Wang L; Yuan S; Sun L
    Eur J Pharmacol; 2018 Oct; 837():81-87. PubMed ID: 30025811
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ASCT2/SLC1A5 controls glutamine uptake and tumour growth in triple-negative basal-like breast cancer.
    van Geldermalsen M; Wang Q; Nagarajah R; Marshall AD; Thoeng A; Gao D; Ritchie W; Feng Y; Bailey CG; Deng N; Harvey K; Beith JM; Selinger CI; O'Toole SA; Rasko JE; Holst J
    Oncogene; 2016 Jun; 35(24):3201-8. PubMed ID: 26455325
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical Role of ASCT2 (SLC1A5) in KRAS-Mutated Colorectal Cancer.
    Toda K; Nishikawa G; Iwamoto M; Itatani Y; Takahashi R; Sakai Y; Kawada K
    Int J Mol Sci; 2017 Jul; 18(8):. PubMed ID: 28749408
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ablation of the
    Bröer A; Gauthier-Coles G; Rahimi F; van Geldermalsen M; Dorsch D; Wegener A; Holst J; Bröer S
    J Biol Chem; 2019 Mar; 294(11):4012-4026. PubMed ID: 30635397
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting ASCT2-mediated glutamine uptake blocks prostate cancer growth and tumour development.
    Wang Q; Hardie RA; Hoy AJ; van Geldermalsen M; Gao D; Fazli L; Sadowski MC; Balaban S; Schreuder M; Nagarajah R; Wong JJ; Metierre C; Pinello N; Otte NJ; Lehman ML; Gleave M; Nelson CC; Bailey CG; Ritchie W; Rasko JE; Holst J
    J Pathol; 2015 Jul; 236(3):278-89. PubMed ID: 25693838
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeted Suppression and Knockout of ASCT2 or LAT1 in Epithelial and Mesenchymal Human Liver Cancer Cells Fail to Inhibit Growth.
    Bothwell PJ; Kron CD; Wittke EF; Czerniak BN; Bode BP
    Int J Mol Sci; 2018 Jul; 19(7):. PubMed ID: 30029480
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Effect of ASCT2 gene knock-down by shRNA on biological behaviors of colorectal cancer cells].
    Cai C; Zeng B; Zeng J; Xin H; Tang C
    Zhonghua Wei Chang Wai Ke Za Zhi; 2017 Apr; 20(4):450-454. PubMed ID: 28440528
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting ASCT2-mediated glutamine metabolism inhibits proliferation and promotes apoptosis of pancreatic cancer cells.
    Wang W; Pan H; Ren F; Chen H; Ren P
    Biosci Rep; 2022 Mar; 42(3):. PubMed ID: 35237783
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ASCT2 overexpression is associated with poor survival of OSCC patients and ASCT2 knockdown inhibited growth of glutamine-addicted OSCC cells.
    Luo Y; Li W; Ling Z; Hu Q; Fan Z; Cheng B; Tao X
    Cancer Med; 2020 May; 9(10):3489-3499. PubMed ID: 32162845
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oncogenic KRAS mutations enhance amino acid uptake by colorectal cancer cells via the hippo signaling effector YAP1.
    Kandasamy P; Zlobec I; Nydegger DT; Pujol-Giménez J; Bhardwaj R; Shirasawa S; Tsunoda T; Hediger MA
    Mol Oncol; 2021 Oct; 15(10):2782-2800. PubMed ID: 34003553
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of glucose metabolism prevents glycosylation of the glutamine transporter ASCT2 and promotes compensatory LAT1 upregulation in leukemia cells.
    Polet F; Martherus R; Corbet C; Pinto A; Feron O
    Oncotarget; 2016 Jul; 7(29):46371-46383. PubMed ID: 27344174
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of the glutamine transporter ASCT2 in antineoplastic therapy.
    Teixeira E; Silva C; Martel F
    Cancer Chemother Pharmacol; 2021 Apr; 87(4):447-464. PubMed ID: 33464409
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Deletion of Amino Acid Transporter ASCT2 (SLC1A5) Reveals an Essential Role for Transporters SNAT1 (SLC38A1) and SNAT2 (SLC38A2) to Sustain Glutaminolysis in Cancer Cells.
    Bröer A; Rahimi F; Bröer S
    J Biol Chem; 2016 Jun; 291(25):13194-205. PubMed ID: 27129276
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lobetyolin inhibits the proliferation of breast cancer cells
    Chen Y; Tian Y; Jin G; Cui Z; Guo W; Zhang X; Liu X
    Hum Exp Toxicol; 2021 Dec; 40(12):2074-2086. PubMed ID: 34075790
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ASCT2 silencing regulates mammalian target-of-rapamycin growth and survival signaling in human hepatoma cells.
    Fuchs BC; Finger RE; Onan MC; Bode BP
    Am J Physiol Cell Physiol; 2007 Jul; 293(1):C55-63. PubMed ID: 17329400
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Variant of SLC1A5 Is a Mitochondrial Glutamine Transporter for Metabolic Reprogramming in Cancer Cells.
    Yoo HC; Park SJ; Nam M; Kang J; Kim K; Yeo JH; Kim JK; Heo Y; Lee HS; Lee MY; Lee CW; Kang JS; Kim YH; Lee J; Choi J; Hwang GS; Bang S; Han JM
    Cell Metab; 2020 Feb; 31(2):267-283.e12. PubMed ID: 31866442
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting of glutamine transporter ASCT2 and glutamine synthetase suppresses gastric cancer cell growth.
    Ye J; Huang Q; Xu J; Huang J; Wang J; Zhong W; Chen W; Lin X; Lin X
    J Cancer Res Clin Oncol; 2018 May; 144(5):821-833. PubMed ID: 29435734
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ASCT1 and ASCT2: Brother and Sister?
    Scalise M; Console L; Cosco J; Pochini L; Galluccio M; Indiveri C
    SLAS Discov; 2021 Oct; 26(9):1148-1163. PubMed ID: 34269129
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.